Limited Tickets Remaining. Secure Your Pass Today

What Is the NeoAg Summit?

Running virtually for the 5th year, the Neoantigen Based Therapies Summit is the only industry-focused meeting dedicated solely to the full end-to-end development and commercialization of neoantigen-based cancer immunotherapies.

Join this exclusive community of over 180+ leading industry experts, and navigate three tracks of content, as we discuss how to maximise immunogenicity, and streamline manufacturing processes to improve the clinical and commercial development of neoantigen based immunotherapies.

 

A Snapshot of Attending Companies

Attending companies banner

Expert Speakers Include

Agnete Fredriksen

Chief Scientific Officer

Vaccibody

Andrew Allen

Chief Executive Officer

Gritstone Oncology

Eric Halioua

President & Chief Executive Officer

PDC*line Pharma

Jessica Fletchner

Chief Scientific Officer

Genocea

Heinz Lubenau

Chief Operating Officer

Vaximm

Marit van Buuren

Director, T-cell Immunology

BioNTech

Nicolas Poirier

Chief Scientific Officer

OSE Immunotherapeutics

Peter Joyce

Chief Executive Officer, Co-Founder

Grey Wolf Therapeutics

Hear What Our Attendees Say

"Great opportunity to learn how to develop and accelerate neoantigen related products not  only  from speakers but also participants and partners."

BrightPath Biotherapeutics

"The Neoantigen Summit is the focal point for updates in the cancer neoantigen vaccine field and should be attended by everybody with a keen interest in the field."

Vaccibody

Proud To Partner With

Industry Development Partner:
Expertise Partners:
Program Partners:
Exhibitors: